LaonMedi, LaonPeople Subsidiary, Signs Software Development & Supply Agreement with DIO

“Global marketing and licensing collaboration expected to drive the K-Dental trend”

[DIO Vice President Kang Jung-moon (left) and LaonMedi CEO Suk-Joong Lee sign the agreement.]

LaonMedi, the AI-powered medical subsidiary of LaonPeople (CEO Suk-Joong Lee), announced on the 21st that it has signed an agreement with global digital implant leader DIO for the development and supply of dental software. The signing ceremony was held at LaonPeople’s headquarters in Gwacheon, marking the start of full-scale collaboration.

Under the agreement, the two companies will cooperate in multiple areas, including enhancing the setup and functionality of orthodontic diagnostic software, developing treatment simulation and ordering systems, and expanding into global markets through joint marketing and licensing initiatives.

LaonMedi plans to apply its AI-based digital diagnostic and treatment technologies—now gaining strong attention in the dental field—to orthodontic treatment. The company aims to further advance its technology through AI software adoption and clinical applications, including the development and provision of clear aligners.
DIO, meanwhile, will integrate LaonMedi’s AI-powered orthodontic setup software “Laon Ortho” into its clear aligner production workflow. By leveraging AI-driven clinical data and operational know-how, DIO expects to dramatically reduce production and processing time for aligners, significantly improving work efficiency and manufacturing productivity.

A LaonMedi representative stated:
“Through this partnership with DIO, we aim to enhance the competitiveness of domestic AI software and elevate Korea’s medical technologies to the next level. We plan to pioneer global markets and strengthen the position of K-Dental as a global trend.”
The representative added, “After unveiling our AI-based automated diagnostic feature ‘One Click’ at the Korean Association of Orthodontists last year, and presenting advanced solutions at both IDS 2025—the world’s largest dental exhibition—and SIDEX 2025, interest from the dental and related industries has surged. We will continue improving technological competitiveness and expanding market presence.”

LaonMedi’s technological capabilities have been validated through its U.S. FDA certification, enabling the company to secure KRW 4.8 billion in investment and expand its competitiveness in both domestic and global markets.
DIO, operating in more than 70 countries, including key implant markets such as the United States, China, and India, is expected to create strong synergy with LaonMedi in areas such as dental software, medical technology, and global licensing through this partnership.